{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T11:12:42Z","timestamp":1771067562186,"version":"3.50.1"},"reference-count":26,"publisher":"BMJ","issue":"8","license":[{"start":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T00:00:00Z","timestamp":1691452800000},"content-version":"unspecified","delay-in-days":7,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2023,7,27]]},"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To explore whether monoclonal antibodies (MAb) administered to high-risk patients with COVID-19 during the first week of illness prevent postacute sequelae of SARS-CoV-2 infection.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design<\/jats:title>\n                    <jats:p>Retrospective cohort study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Setting<\/jats:title>\n                    <jats:p>USA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Participants<\/jats:title>\n                    <jats:p>A sample of 3809 individuals who received MAbs and a matched one-to-one comparison group from a set of 327\u2009079 eligible patients who did not receive MAb treatment were selected from a deidentified administrative data set from commercial and Medicare Advantage health plan enrollees in the USA, including claims and outpatient laboratory data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Individuals who received MAb were 28% less likely to be hospitalised (HR=0.72, 95% CI 0.58 to 0.89) and 41% less likely to be admitted to the intensive care unit (HR=0.59, 95% CI 0.38 to 0.89) 30 days from SARS-CoV-2 diagnosis compared with individuals who did not receive MAb. A higher proportion of individuals given MAb therapy received care for clinical sequelae in the postacute phase (p=0.018).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While MAb therapy was associated with benefits in the acute period, the benefit of therapy did not extend into the postacute period and did not reduce risk for clinical sequelae.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2022-069247","type":"journal-article","created":{"date-parts":[[2023,8,8]],"date-time":"2023-08-08T11:13:54Z","timestamp":1691493234000},"page":"e069247","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":7,"title":["Does monoclonal antibody treatment for COVID-19 impact short and long-term outcomes in a large generalisable population? A retrospective cohort study in the USA"],"prefix":"10.1136","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5853-6906","authenticated-orcid":false,"given":"Daniel","family":"Griffin","sequence":"first","affiliation":[{"name":"Department of Medicine, Columbia University Vagelos College of Physicians and Surgeons, New York City, New York, USA"},{"name":"Department of Medicine, Optum Health, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chace","family":"McNeil","sequence":"additional","affiliation":[{"name":"Optum Health, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James","family":"Okusa","sequence":"additional","affiliation":[{"name":"Optum Health, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Diana","family":"Berrent","sequence":"additional","affiliation":[{"name":"Survivor Corps, New York City, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yinglong","family":"Guo","sequence":"additional","affiliation":[{"name":"Optum Health, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah E","family":"Daugherty","sequence":"additional","affiliation":[{"name":"Optum Health, Eden Prairie, Minnesota, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2023,8,8]]},"reference":[{"key":"2025121221222410000_13.8.e069247.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.1585"},{"key":"2025121221222410000_13.8.e069247.2","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2021.101158","article-title":"Bnt162b2 mRNA COVID-19 vaccination in immunocompromised patients: A prospective cohort study","volume":"41","author":"Rahav","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025121221222410000_13.8.e069247.3","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n2860","article-title":"Covid-19: Astrazeneca says its antibody drug Azd7442 is effective for preventing and reducing severe illness","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"key":"2025121221222410000_13.8.e069247.4","doi-asserted-by":"crossref","unstructured":"Jones BE , Brown-Augsburger PL , Corbett KS , et al . LY-Cov555, a rapidly isolated potent neutralizing antibody, provides protection in a non-human Primate model of SARS-Cov-2 infection. bioRxiv 2020:2020.09.30.318972. doi:10.1101\/2020.09.30.318972","DOI":"10.1101\/2020.09.30.318972"},{"key":"2025121221222410000_13.8.e069247.5","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe2402"},{"key":"2025121221222410000_13.8.e069247.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMe1915350"},{"key":"2025121221222410000_13.8.e069247.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2029849"},{"key":"2025121221222410000_13.8.e069247.8","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1056\/NEJMoa2033130","article-title":"A neutralizing Monoclonal antibody for hospitalized patients with COVID-19","volume":"384","author":"Lundgren","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121221222410000_13.8.e069247.9","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1056\/NEJMoa2107934","article-title":"Early treatment for COVID-19 with SARS-Cov-2 neutralizing antibody Sotrovimab","volume":"385","author":"Gupta","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121221222410000_13.8.e069247.10","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2035002"},{"key":"2025121221222410000_13.8.e069247.11","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2109682","article-title":"Subcutaneous REGEN-COV antibody combination to prevent COVID-19. reply","volume":"385","author":"O\u2019Brien","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121221222410000_13.8.e069247.12","doi-asserted-by":"crossref","unstructured":"Johnson G , Lim S , Griffin DO , et al . The impact of COVID-19 Monoclonal antibody therapy on progression to hospitalization in a population with a high percentage of the SARS-Cov-2 alpha variant. MARJ 2022;10. doi:10.18103\/mra.v10i2.2703 Available: https:\/\/esmed.org\/MRA\/mra\/issue\/view\/134","DOI":"10.18103\/mra.v10i2.2703"},{"key":"2025121221222410000_13.8.e069247.13","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.n1098","article-title":"Risk of clinical sequelae after the acute phase of SARS-Cov-2 infection: retrospective cohort study","volume":"373","author":"Daugherty","year":"2021","journal-title":"BMJ"},{"key":"2025121221222410000_13.8.e069247.14","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.15585\/mmwr.mm7037a2","article-title":"Post-acute sequelae of SARS-Cov-2 infection among adults aged \u226518 years\u2014long beach, California, April 1\u2013December 10, 2020","volume":"70","author":"Yomogida","year":"2021","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"2025121221222410000_13.8.e069247.15","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10225298","article-title":"Long-term symptoms among hospitalized COVID-19 patients 48 weeks after discharge\u2014a prospective cohort study","volume":"10","author":"M\u00f8lhave","year":"2021","journal-title":"J Clin Med"},{"key":"2025121221222410000_13.8.e069247.16","unstructured":"World Health Organization . A clinical case definition of post COVID-19 condition by a Delphi consensus. 2021. Available: https:\/\/www.who.int\/publications-detail-redirect\/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1"},{"key":"2025121221222410000_13.8.e069247.17","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1093\/cid\/ciab408","article-title":"Population-based estimates of post-acute sequelae of severe acute respiratory syndrome Coronavirus 2 (SARS-Cov-2) infection (PASC) prevalence and characteristics","volume":"73","author":"Hirschtick","year":"2021","journal-title":"Clin Infect Dis"},{"key":"2025121221222410000_13.8.e069247.18","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1001\/jama.2020.24415","article-title":"An EUA for Bamlanivimab\u2014A Monoclonal antibody for COVID-19","volume":"325","year":"2021","journal-title":"JAMA"},{"key":"2025121221222410000_13.8.e069247.19","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1056\/NEJMoa2102685","article-title":"Bamlanivimab plus Etesevimab in mild or moderate COVID-19","volume":"385","author":"Dougan","year":"2021","journal-title":"N Engl J Med"},{"key":"2025121221222410000_13.8.e069247.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2031364"},{"key":"2025121221222410000_13.8.e069247.21","doi-asserted-by":"crossref","first-page":"101102","DOI":"10.1016\/j.eclinm.2021.101102","article-title":"Casirivimab\u2013Imdevimab treatment is associated with reduced rates of hospitalization among high-risk patients with mild to moderate Coronavirus Disease-19.","volume":"40","author":"Razonable","year":"2021","journal-title":"EClinicalMedicine"},{"key":"2025121221222410000_13.8.e069247.22","article-title":"SARS\u2010Cov\u20102\u2010Neutralising Monoclonal antibodies for treatment of COVID\u201019","volume":"9","author":"Kreuzberger","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"2025121221222410000_13.8.e069247.23","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2021-068414","article-title":"Risk of persistent and new clinical sequelae among adults aged 65 years and older during the post-acute phase of SARS-Cov-2 infection: retrospective cohort study","volume":"376","author":"Cohen","year":"2022","journal-title":"BMJ"},{"key":"2025121221222410000_13.8.e069247.24","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2020.17703","article-title":"Comparison of international classification of diseases and related health problems, tenth revision codes with electronic medical records among patients with symptoms of Coronavirus disease 2019","volume":"3","author":"Crabb","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025121221222410000_13.8.e069247.25","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1001\/jamainternmed.2023.0743","article-title":"Association of treatment with Nirmatrelvir and the risk of post-COVID-19 condition","volume":"183","author":"Xie","year":"2023","journal-title":"JAMA Intern Med"},{"key":"2025121221222410000_13.8.e069247.26","doi-asserted-by":"crossref","unstructured":"Xie Y , Choi T , Al-Aly Z . n.d. Nirmatrelvir and the risk of post-acute sequelae of COVID-19. Infectious Diseases (except HIV\/AIDS) doi:10.1101\/2022.11.03.22281783","DOI":"10.1101\/2022.11.03.22281783"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2022-069247","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,13]],"date-time":"2025-12-13T05:22:36Z","timestamp":1765603356000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2022-069247"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":26,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8,8]]},"published-print":{"date-parts":[[2023,8]]}},"alternative-id":["10.1136\/bmjopen-2022-069247"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2022-069247","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]}}}